Showing results (61-70 of 211) with videos related to
Sort By:
Pageof 22
Current Opinion in Cardiology|May 11, 2012
Low-density lipoprotein-lowering strategies: target versus maximalist versus population percentileAllan D Sniderman, Jacqueline De Graaf, Patrick CoutureEuropean Heart Journal|August 12, 2025
Myocardial compression and recoil as determinants of coronary blood flowAllan D Sniderman, Kevin J Lachapelle, George ThanassoulisThe American Journal of Cardiology|January 12, 2005
Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project)Paul L Canner, Curt D Furberg, Michael L Terrin, et al.Pharmacoepidemiology and Drug Safety|February 11, 2016
Completeness of serious adverse drug event reports received by the US Food and Drug Administration in 2014Thomas J Moore, Curt D Furberg, Donald R Mattison, et al.JAMA|December 2, 2004
Potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysisBruce M Psaty, Curt D Furberg, Wayne A Ray, et al.Trials|March 25, 2006
Lead editorial: trials - using the opportunities of electronic publishing to improve the reporting of randomised trialsDouglas G Altman, Curt D Furberg, Jeremy M Grimshaw, et al.Journal of Clinical Epidemiology|August 6, 2002
Predictors of subsequent coronary events, stroke, and death among survivors of first hospitalized myocardial infarctionRobert C Kaplan, Susan R Heckbert, Curt D Furberg, et al.American Journal of Hypertension|April 4, 2013
Renin-angiotensin system blockers may create more risk than reward for sodium-depleted cardiovascular patients with high plasma renin levelsJean E Sealey, Michael H Alderman, Curt D Furberg, et al.Journal of Clinical Lipidology|December 16, 2014
The Risk-Benefit Paradigm vs the Causal Exposure Paradigm: LDL as a primary cause of vascular diseasePeter P Toth, George Thanassoulis, Ken Williams, et al.Journal of Clinical Lipidology|December 22, 2015
JCL roundtable: Apolipoproteins as causative elements in vascular diseaseW Virgil Brown, Frank M Sacks, Allan D SnidermanPageof 22